PSMA and SSTR2 Dual-Targeting Theranostic Agents for Neuroendocrine-Differentiated Prostate Cancer (NEPC)
Journal of Medicinal Chemistry · 2025
DOI: 10.1021/acs.jmedchem.4c02768 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2025. Verfasst von Wenbin Jin und 8 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Radiopharmaceuticals, Ministry of Education, College of Chemistry, Beijing Normal University, Beijing 100875, China. Hauptthemen laut MEDLINE: Receptors, Somatostatin, Antigens, Surface, Glutamate Carboxypeptidase II, Lutetium. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Chinese Academy of Medical Science Innovation, National High-Level Hospital Clinical Research Funding.
Abstract (Originalsprache)
Radioactive prostate-specific membrane antigen (PSMA)-targeting agents are clinically useful for the diagnosis and treatment of patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC). Neuroendocrine-differentiated prostate cancer (NEPC), a highly aggressive subtype that is strongly associated with a poor clinical prognosis, may present with reduced PSMA expression and evade detection with PSMA-targeted agents. Several studies have shown elevated uptake of somatostatin receptor 2 (SSTR2) ligands in PSMA-negative NEPC. By combining a SSTR2-targeting peptide, JR11, with previously reported PSMA-targeting ligands, P16-093 and P17-087, [68Ga]Ga-1 and [68Ga]Ga/[177Lu]Lu-2 were designed and synthesized. The cell uptake of [68Ga]Ga-1 was comparable to [68Ga]Ga-P16-093 in PSMA-positive cell lines, while [68Ga]Ga-1 and [68Ga]Ga-2 showed a positive but slightly lower uptake than [68Ga]Ga-DOTA-TATE in SSTR2-positive cell lines. In vivo studies in SSTR2+ or PSMA+ tumor-bearing mice demonstrated that [68Ga]Ga-1 and [68Ga]Ga/[177Lu]Lu-2 showed positive uptake for both SSTR2+ and PSMA+ tumors. These dual-targeting radiotracers are potentially valuable for the diagnosis and radioligand therapy of NEPC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Radiopharmaceuticals, Ministry of Education, College of Chemistry, Beijing Normal University, Beijing 100875, China.
- Institute of Biomedical Engineering, Shenzhen Bay Laboratory, Shenzhen, Guangdong 518000, China.
- Department of Nuclear Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Peking Union Medical College Hospital, Ch…
- Department of Radiology, University of Pennsylvania, Philadelphia, Pennsylvania 19104, United States.
ORCID-Profile: Zhaohui Zhu, Hank F Kung
Förderung
- National Natural Science Foundation of China
- Chinese Academy of Medical Science Innovation
- National High-Level Hospital Clinical Research Funding
Zitieren
APA
Jin, W., Yan, L., Li, L., Luo, Y., Qiao, J., Peng, Q., Zhu, Z., Zhu, L., & Kung, H. F. (2025). PSMA and SSTR2 Dual-Targeting Theranostic Agents for Neuroendocrine-Differentiated Prostate Cancer (NEPC). Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c02768
Vancouver
Jin W, Yan L, Li L, Luo Y, Qiao J, Peng Q, et al. PSMA and SSTR2 Dual-Targeting Theranostic Agents for Neuroendocrine-Differentiated Prostate Cancer (NEPC). Journal of Medicinal Chemistry. 2025. doi:10.1021/acs.jmedchem.4c02768
BibTeX
@article{Jin2025,
author = {Jin, Wenbin and Yan, Li and Li, Linlin and Luo, Yang and Qiao, Jinping and Peng, Qiyu and Zhu, Zhaohui and Zhu, Lin and Kung, Hank F},
title = {PSMA and SSTR2 Dual-Targeting Theranostic Agents for Neuroendocrine-Differentiated Prostate Cancer (NEPC)},
journal = {Journal of Medicinal Chemistry},
year = {2025},
doi = {10.1021/acs.jmedchem.4c02768}
}
EUVIMED